[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  DonCorleone77 [@CorleoneDon77](/creator/twitter/CorleoneDon77) on x 5427 followers Created: 2025-07-22 12:55:01 UTC $DHR Attached is page X of a 5-page Bank of America analyst report on DHR issued today entitled: "First Look: Solid 2Q, FY25 org sales reit., Adj EPS raised, CFO transition announced" Bank of America has a 'Buy' rating on DHR with a $XXX price target. Bank of America's summary statement regarding DHR in the report includes the following: "2Q25: Sales +2% ahead of St, Adj EPS +16c ahead of St: This morning DHR reported 2Q25 total revenues of $5,936mn vs BofAe/Street $5,903/$5,837mn. Organic sales for 2Q were +1.5%, in-line with our estimate (and +LSD guide). Bioprocessing grew +HSD (in-line with our expectation). On the P&L, Gross Margin was XXXX% (vs. BofAe 57.7%) and operating margin was XXXX% (vs. BofAe 25.2%), both ahead of expectations. Adj EPS were $1.80, ahead of our/Street estimates of $XXXX (see Exhibit 1). FCF in the quarter was ~$2.2bn. All segments broadly in-line with guide / expectations: Biotechnology segment was +6% core (vs guide of +7%). Life Sciences was -XXX% (vs guide of -LSD/-MSD) with a -LSD decline in instruments. Dx was +2% (vs guide of +LSD) and clinical Dx grew +MSD excluding China. DHR called out respiratory revenues of ~$300mn for CPHD (vs. guide of $250mn). Overall, we view the 2Q print as solid. Sales guide unchanged (+3% core); EPS midpt now $7.75: For FY25, DHR continues to expect base core revenues to be +3%, with no change to segment contribution to FY and continued expectation of ~$1.7bn from CPHD respiratory. FY25 Adj. EPS guide was raised to $7.70-$7.80 (from $7.60-$7.75), aided by a more favorable expected FX environment (now expecting +1% to sales, vs -XXX% prior). For 3Q, base core business growth is guided to +LSD (in-line with BofAe), with similar demand trends from 2Q and +HSD BP growth. Adj OpM is expected to be ~25.5% in 3Q. -- Price Objective Basis: Our $XXX price objective (PO) is based on a discounted cash flow (DCF) analysis (assumes XXX% weighted-average cost of capital-WACC, X% terminal growth rate). We believe this discount rate is appropriate as several key acquisitions (e.g., GE Life Sciences, Aldevron, Cepheid) have significantly accelerated Danaher's organic revenue growth, enhanced margins, lowered the company's cyclical exposure, and increased the percentage of sales from recurring revenues. -- Downside risks: F/X risks, economic & macro risks, cyclical exposure, geopolitical risks, reductions in R&D funding, customer consolidation, a slowdown in bioprocess demand, competitive risks, deal integration risks. -- Upside risks: Faster resolution of near-term bioprocessing headwinds, or favorable capital deployment by the company." (Page X is not available here as X does not allow me to post pages from reports on this platform) XXX engagements  **Related Topics** [eps](/topic/eps) [reit](/topic/reit) [united states](/topic/united-states) [bank of](/topic/bank-of) [$dhr](/topic/$dhr) [stocks healthcare](/topic/stocks-healthcare) [bank of america](/topic/bank-of-america) [stocks financial services](/topic/stocks-financial-services) [Post Link](https://x.com/CorleoneDon77/status/1947641534330847417)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
DonCorleone77 @CorleoneDon77 on x 5427 followers
Created: 2025-07-22 12:55:01 UTC
$DHR
Attached is page X of a 5-page Bank of America analyst report on DHR issued today entitled:
"First Look: Solid 2Q, FY25 org sales reit., Adj EPS raised, CFO transition announced"
Bank of America has a 'Buy' rating on DHR with a $XXX price target.
Bank of America's summary statement regarding DHR in the report includes the following:
"2Q25: Sales +2% ahead of St, Adj EPS +16c ahead of St:
This morning DHR reported 2Q25 total revenues of $5,936mn vs BofAe/Street $5,903/$5,837mn. Organic sales for 2Q were +1.5%, in-line with our estimate (and +LSD guide). Bioprocessing grew +HSD (in-line with our expectation).
On the P&L, Gross Margin was XXXX% (vs. BofAe 57.7%) and operating margin was XXXX% (vs. BofAe 25.2%), both ahead of expectations. Adj EPS were $1.80, ahead of our/Street estimates of $XXXX (see Exhibit 1). FCF in the quarter was ~$2.2bn.
All segments broadly in-line with guide / expectations:
Biotechnology segment was +6% core (vs guide of +7%). Life Sciences was -XXX% (vs guide of -LSD/-MSD) with a -LSD decline in instruments. Dx was +2% (vs guide of +LSD) and clinical Dx grew +MSD excluding China. DHR called out respiratory revenues of ~$300mn for CPHD (vs. guide of $250mn). Overall, we view the 2Q print as solid.
Sales guide unchanged (+3% core); EPS midpt now $7.75:
For FY25, DHR continues to expect base core revenues to be +3%, with no change to segment contribution to FY and continued expectation of ~$1.7bn from CPHD respiratory. FY25 Adj. EPS guide was raised to $7.70-$7.80 (from $7.60-$7.75), aided by a more favorable expected FX environment (now expecting +1% to sales, vs -XXX% prior).
For 3Q, base core business growth is guided to +LSD (in-line with BofAe), with similar demand trends from 2Q and +HSD BP growth. Adj OpM is expected to be ~25.5% in 3Q.
-- Price Objective Basis:
Our $XXX price objective (PO) is based on a discounted cash flow (DCF) analysis (assumes XXX% weighted-average cost of capital-WACC, X% terminal growth rate). We believe this discount rate is appropriate as several key acquisitions (e.g., GE Life Sciences, Aldevron, Cepheid) have significantly accelerated Danaher's organic revenue growth, enhanced margins, lowered the company's cyclical exposure, and increased the percentage of sales from recurring revenues.
-- Downside risks:
F/X risks, economic & macro risks, cyclical exposure, geopolitical risks, reductions in R&D funding, customer consolidation, a slowdown in bioprocess demand, competitive risks, deal integration risks.
-- Upside risks:
Faster resolution of near-term bioprocessing headwinds, or favorable capital deployment by the company."
(Page X is not available here as X does not allow me to post pages from reports on this platform)
XXX engagements
Related Topics eps reit united states bank of $dhr stocks healthcare bank of america stocks financial services